OC5 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Financial GuidanceFY26 guidance implies 2H26 NPAT growth of +13-25%.
Market GrowthThe Nucleus Nexa is the first 'smart' implant to market, expected to attract both physicians and patients and see double-digit growth for implants.
Product LaunchWith the launch of a new implant – the Nucleus Nexa – offering an enhanced patient experience, there is optimism that the company can sustain its market-leading position.
Bears Say
Market SentimentUncertainty around near-term services growth has led to a downgrade of COH shares from Buy to Neutral.
Product VolumeProcessors experienced a decline in volumes due to a mix of cost of living and other factors, making the outlook for services sales less optimistic.
Sales EstimatesMid-term sales estimates fall 5-6% on lower services sales growth, which resulted in a decrease in the price target from AUD350 to AUD320.
Cochlear News
OC5 FAQ
What was Cochlear Limited’s price range in the past 12 months?
Currently, no data Available
What is Cochlear Limited’s market cap?
Cochlear Limited’s market cap is CHF5.41B.
When is Cochlear Limited’s upcoming earnings report date?
Cochlear Limited’s upcoming earnings report date is Feb 16, 2027 which is in 162 days.
How were Cochlear Limited’s earnings last quarter?
Cochlear Limited released its earnings results on Aug 17, 2026. The company reported CHF1.136 earnings per share for the quarter, beating the consensus estimate of CHF0.982 by CHF0.153.
Is Cochlear Limited overvalued?
According to Wall Street analysts Cochlear Limited’s price is currently Undervalued.
Does Cochlear Limited pay dividends?
Cochlear Limited does not currently pay dividends.
What is Cochlear Limited’s EPS estimate?
Cochlear Limited’s EPS estimate is 1.55.
How many shares outstanding does Cochlear Limited have?
Cochlear Limited has 65,398,920 shares outstanding.
What happened to Cochlear Limited’s price movement after its last earnings report?
Cochlear Limited reported an EPS of CHF1.136 in its last earnings report, beating expectations of CHF0.982. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cochlear Limited?
Currently, no hedge funds are holding shares in CH:OC5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cochlear Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF81.49 (― Upside)
CHF81.49 (― Upside)
Blogger Sentiment
Bullish
CH:OC5 Sentiment 85%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth CHF283.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.37%
12-Months-Change
Fundamentals
Return on Equity
2.76%
Trailing 12-Months
Asset Growth
-2.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cochlear Limited
Globally, Cochlear Limited specializes in the development and provision of implantable auditory solutions for both children and adults. The company's diverse offerings include advanced cochlear implant systems, upgrades for sound processors, bone conduction devices, and a wide array of accessories and other related items. Established in 1981, its global operations are directed from its headquarters in Sydney, Australia.
OC5 Company Deck
OC5 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call outlined clear strategic progress: a highly successful Nexa product launch, meaningful unit growth, strong services expansion in developed markets, disciplined cash and cost management, and continued heavy R&D investment into attractive pipeline programs (TICI, drug-eluting electrodes). However, material near-term challenges remain — a 3ppt gross margin decline to 71%, an underlying net profit margin below target (14% vs 18% medium-term goal), Western Europe weakness, China pricing headwinds, non-cash write-downs and FY'27 FX headwinds. Management has responded with cost optimization, targeted growth re-investment (DTC and professional referral pilots) and a conservative FY'27 outlook (low single-digit revenue growth; underlying NP $330m–$350m). Overall the call balanced tangible product and pipeline upside with notable geopolitical, reimbursement and margin pressures.View all CH:OC5 earnings summariesOC5 Stock 12 Month Forecast
Average Price Target
―Nova Eye Medical
―
Compumedics Limited
―
Somnomed Limited
―
Control Bionics Ltd.
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―